AnaCardio strengthens its organization
Stockholm Sweden – October 25, 2021 Karolinska Development’s portfolio company AnaCardio strengthens its organization to facilitate clinical trial of the drug candidate AC01 in heart failure. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the portfolio company AnaCardio has strengthened its organization in preparation for the initiation of a phase 1b/2a study of its […]
AnaCardio appoints Patrik Strömberg as CEO
Stockholm, Sweden, 22 October 2021 AnaCardio appoints Patrik Strömberg as CEO.AnaCardio AB announces today that Patrik Strömberg has been appointed Chief Executive Officer effective as of September 1, 2021. Patrik Strömberg joins AnaCardio from his previous role as Vice President, External Innovation, Sourcing & Evaluation at Swedish Orphan Biovitrum AB (Sobi). Patrik has extensive experience […]
Karolinska Development expands its portfolio through new investment in AnaCardio
Stockholm, Sweden – June 17, 2021 Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that the company has acquired approximately 21 percent of the shares in AnaCardio AB. The new portfolio company develops drugs for the treatment of heart failure, based on groundbreaking research from Karolinska Institutet. The company’s most advanced project is deemed to […]